Last reviewed · How we verify
Effect Of Trimetazidine On Left Ventricular Functions and Inflammatory Markers of Patients With Type 2 Diabetes Mellitus
Subclinical diastolic dysfunction represents the early phase of diabetic cardiomyopathy and is a common complication among type 2 diabetic patients that increases mortality rate among those patients and can progress to heart failure with preserved ejection fraction. Trimetazidine is an anti-ischemic agent widely used in the treatment of coronary artery disease and it has positive effects on energy metabolism in heart failure. Therefore, we hypothesized that trimetazidine may have potential benefit on the amelioration of the inflammatory insult and improving the clinical outcomes in patients with diabetic cardiomyopathy especially if applied in the early stages.
Details
| Lead sponsor | Ain Shams University |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 60 |
| Start date | 2022-09-18 |
| Completion | 2023-09 |
Conditions
- Diabetes Mellitus, Type 2
- Diabetic Cardiomyopathies
Interventions
- Trimetazidine Dihydrochloride
- Placebo
Primary outcomes
- Change from baseline Left ventricular functions at 3 months — at baseline and after three months of intervention
assessed using echocardiographic and tissue doppler evaluation
Countries
Egypt